Postmarketing Periodic Reports Should Be Biannual, Not Quarterly - Ligand
Executive Summary
Postmarketing periodic adverse event reports should be required every six months following product approval instead of every three months, Ligand suggested in recent comments on FDA's draft guidance "Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines."
You may also be interested in...
FDA Plans Proposed Rule To Amend Expedited Safety Reporting Regulations
FDA is planning to propose additional amendments to its expedited safety reporting regulations based on guidelines issued by the International Conference on Harmonization.
FDA Proposed Rule Will Require MedDRA for Postmarketing AE Reporting
FDA's Suspected Adverse Drug Reaction proposed rule will seek to require the use of MedDRA terminology in submissions of postmarketing adverse event reports, the agency told a Drug Information Association workshop on MedDRA implementation Oct. 30 in Washington, D.C.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011